IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Immunovant, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.62+0.89 (+3.33%)
Close on Oct 19, 2026
- Market cap
- $5.68B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
53.5%
110M of 207M shares
Institutional holders
226
39 new, 24 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
1 buys · 55 sales
Net bought $334.12M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 9,500,000 | 5.59% | 13G (passive) | Mar 19, 2025 |
| FMR LLC | 17,078,093 | 10.10% | 13G (passive) amendment | Feb 28, 2025 |
| Abigail P. Johnson | 14,729,555 | 8.40% | 13G (passive) amendment | Sep 30, 2025 |
| Roivant Sciences Ltd. | 113,327,007 | 55.90% | 13D (active) amendment | Dec 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMVT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 16,186,469 | 7.84% | $623.66M | −761,419 | 0.03% |
| Deep Track Capital, LP | 9,341,151 | 4.52% | $359.91M | −2,185,820 | 5.24% |
| BlackRock, Inc. | 7,180,897 | 3.48% | $276.68M | +606,400 | 0.00% |
| Farallon Capital Management LLC | 5,805,000 | 2.81% | $223.67M | +4,259,000 | 1.03% |
| Baker Bros. Advisors LP | 5,435,220 | 2.63% | $209.42M | −22,661 | 1.05% |
| State Street Corp | 4,617,005 | 2.24% | $177.89M | +79,076 | 0.01% |
| Morgan Stanley | 4,534,833 | 2.20% | $174.73M | +657,956 | 0.01% |
| TCG Crossover Management, LLC | 4,457,988 | 2.16% | $171.77M | – | 4.13% |
| Vanguard Portfolio Management LLC | 3,910,509 | 1.89% | $150.67M | +205,604 | 0.01% |
| Vanguard Capital Management LLC | 3,638,681 | 1.76% | $140.20M | +18,631 | 0.00% |
| Jennison Associates LLC | 3,310,238 | 1.60% | $127.54M | +113,533 | 0.08% |
| Rtw Investments, LP | 3,177,849 | 1.54% | $122.44M | – | 1.05% |
| Two Seas Capital LP | 3,148,505 | 1.52% | $121.31M | −53,457 | 2.40% |
| ADAR1 Capital Management, LLC | 2,330,716 | 1.13% | $89.80M | −348,294 | 4.11% |
| Geode Capital Management, LLC | 2,234,602 | 1.08% | $86.12M | +142,500 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 2,222,101 | 1.08% | $85.62K | −1,390,759 | 0.06% |
| Woodline Partners LP | 1,975,869 | 0.96% | $76.13M | – | 0.24% |
| Price T Rowe Associates Inc /Md/ | 1,829,210 | 0.89% | $70.48K | +1,489,603 | 0.01% |
| Goldman Sachs Group Inc | 1,751,183 | 0.85% | $67.47M | −33,924 | 0.01% |
| Armistice Capital, LLC | 1,736,000 | 0.84% | $66.89M | −1,828,916 | 0.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 226 | 110M | 53.5% | 39 / 74 | 79 / 24 | 13M | 14M |
| Q1 2026 | 215 | 111M | 53.9% | 46 / 93 | 40 / 25 | 22M | 12M |
| Q4 2025 | 197 | 109M | 52.9% | 40 / 75 | 54 / 26 | 23M | 9M |
| Q3 2025 | 186 | 95M | 46.1% | 35 / 64 | 51 / 16 | 9M | 10M |
| Q2 2025 | 168 | 96M | 46.6% | 24 / 74 | 47 / 48 | 11M | 10M |
| Q1 2025 | 193 | 95M | 45.9% | 36 / 91 | 43 / 27 | 22M | 9M |
| Q4 2024 | 186 | 82M | 39.8% | 38 / 68 | 61 / 29 | 14M | 11M |
| Q3 2024 | 182 | 80M | 38.6% | 21 / 71 | 66 / 35 | 17M | 8M |
| Q2 2024 | 197 | 76M | 36.6% | 25 / 81 | 66 / 35 | 15M | 15M |
| Q1 2024 | 209 | 75M | 36.3% | 28 / 82 | 79 / 46 | 15M | 11M |
| Q4 2023 | 228 | 72M | 34.6% | 72 / 68 | 72 / 24 | 17M | 13M |
| Q3 2023 | 181 | 68M | 33.0% | 61 / 64 | 44 / 24 | 23M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMVT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 5,098,631 | 2.47% | $169.78M | 0.17% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,600,086 | 1.26% | $100.18M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,576,556 | 1.25% | $99.27M | 0.92% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,190,157 | 1.06% | $84.39M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,881,798 | 0.91% | $72.51M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,402,578 | 0.68% | $46.71M | 0.17% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,113,759 | 0.54% | $37.09M | 0.15% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,086,290 | 0.53% | $41.85M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 991,466 | 0.48% | $38.20M | 0.41% | Jun 30, 2026 |
| PGIM Jennison Small Company Fund | 981,541 | 0.48% | $37.82M | 1.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 932,980 | 0.45% | $36.03M | 0.11% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 887,905 | 0.43% | $34.21M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 787,645 | 0.38% | $30.35M | 0.20% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 642,000 | 0.31% | $24.74M | 0.25% | Jun 30, 2026 |
| iShares Biotechnology ETF | 573,747 | 0.28% | $22.11M | 0.24% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Venker | Chief Executive Officer, Director | 254,280 | 0.12% | Jul 6, 2026 |
| Peter Salzmann | Chief Executive Officer, Director | 1,178,191 | 0.57% | Apr 17, 2025 |
| Tuyl Christopher Van | Chief Legal Officer | 176,545 | 0.09% | Sep 25, 2026 |
| Melanie Gloria | Chief Operating Officer | 219,301 | 0.11% | Aug 21, 2026 |
| Jay S. Stout | Chief Technology Officer | 205,341 | 0.10% | Jul 24, 2026 |
| Tiago Girao | Chief Financial Officer | 240,798 | 0.12% | Jul 24, 2026 |
| Michael Geffner | Chief Medical Officer | 217,958 | 0.11% | Oct 24, 2025 |
| Eva Renee Barnett | Chief Financial Officer | 396,774 | 0.19% | Apr 17, 2025 |
| William L. Macias | Chief Medical Officer | 357,353 | 0.17% | Feb 21, 2025 |
| Mark S. Levine | Chief Legal Officer | 319,228 | 0.15% | Nov 22, 2024 |
| Atul Pande | Director | 138,231 | 0.07% | Aug 28, 2026 |
| Andrew J. Fromkin | Director | 131,400 | 0.06% | May 29, 2026 |
| Robert Graham Susman | Director | 36,394 | 0.02% | May 1, 2026 |
| Douglas J. Hughes | Director | 134,653 | 0.07% | Apr 9, 2026 |
| Jake Bauer | Director | 38,896 | 0.02% | Apr 9, 2026 |
| Frank Torti | Director | 1,009,228 | 0.49% | Apr 9, 2026 |
| Sciences Ltd. Roivant | Director, 10% owner | 113,317,007 | 54.86% | Dec 12, 2025 |
| George V. Migausky | Director | 157,251 | 0.08% | Apr 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tuyl Christopher Van Chief Legal Officer | Sep 23, 2026 | Sale | −2,846 | $36.36 | $103.48K | 176,545 |
| Atul Pande Director | Aug 28, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Atul Pande Director | Aug 28, 2026 | Sale(10b5-1 plan) | −1,500 | $43.27 | $64.91K | 116,731 |
| Melanie Gloria Chief Operating Officer | Aug 20, 2026 | Sale | −3,056 | $44.16 | $134.95K | 219,301 |
| Atul Pande Director | Jul 24, 2026 | Sale(10b5-1 plan) | −1,500 | $39.80 | $59.70K | 116,731 |
| Atul Pande Director | Jul 24, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Tiago Girao Chief Financial Officer | Jul 23, 2026 | Sale | −6,798 | $38.69 | $263.01K | 240,798 |
| Jay S. Stout Chief Technology Officer | Jul 23, 2026 | Sale | −2,857 | $38.69 | $110.54K | 205,341 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −1,906 | $39.53 | $75.34K | 209,779 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −105 | $39.99 | $4.20K | 209,674 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −77 | $39.99 | $3.08K | 208,198 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −1,399 | $39.53 | $55.30K | 208,275 |
| Tuyl Christopher Van Chief Legal Officer | Jul 8, 2026 | Sale | −1,143 | $39.53 | $45.18K | 179,454 |
| Tuyl Christopher Van Chief Legal Officer | Jul 8, 2026 | Sale | −63 | $39.99 | $2.52K | 179,391 |
| Melanie Gloria Chief Operating Officer | Jul 8, 2026 | Sale | −1,930 | $39.53 | $76.29K | 222,463 |
| Melanie Gloria Chief Operating Officer | Jul 8, 2026 | Sale | −106 | $39.99 | $4.24K | 222,357 |
| Eric Venker Chief Executive Officer, Director | Jul 2, 2026 | Sale | −3,092 | $38.48 | $118.98K | 254,280 |
| Eric Venker Chief Executive Officer, Director | Jul 1, 2026 | Option exercise | +92,188 | $14.46 | $1.33M | 344,001 |
| Eric Venker Chief Executive Officer, Director | Jul 1, 2026 | Returned to company | −86,629 | $38.14 | $3.30M | 257,372 |
| Melanie Gloria Chief Operating Officer | Jun 26, 2026 | Sale | −2,966 | $38.95 | $115.53K | 224,393 |
| Melanie Gloria Chief Operating Officer | Jun 26, 2026 | Sale | −14,748 | $38.18 | $563.08K | 227,359 |
| Jay S. Stout Chief Technology Officer | Jun 26, 2026 | Sale | −33,277 | $38.18 | $1.27M | 218,408 |
| Jay S. Stout Chief Technology Officer | Jun 26, 2026 | Sale | −6,723 | $38.94 | $261.79K | 211,685 |
| Atul Pande Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,500 | $38.01 | $57.02K | 116,731 |
| Atul Pande Director | Jun 26, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Option exercise | +17,824 | $15.20 | $270.92K | 198,421 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Sale | −14,982 | $38.19 | $572.16K | 183,439 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Sale | −2,842 | $38.96 | $110.72K | 180,597 |
| Tiago Girao Chief Financial Officer | Jun 26, 2026 | Option exercise | +10,000 | $15.90 | $159.00K | 257,596 |
| Tiago Girao Chief Financial Officer | Jun 26, 2026 | Sale | −10,000 | $38.46 | $384.60K | 247,596 |
| Tuyl Christopher Van Chief Legal Officer | Jun 18, 2026 | Sale | −2,634 | $35.39 | $93.22K | 180,597 |
| Atul Pande Director | Jun 15, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Atul Pande Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,500 | $34.02 | $51.03K | 116,731 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +31,668 | $4.99 | $158.02K | 131,400 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +71,492 | $7.94 | $567.65K | 202,892 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +16,260 | $14.70 | $239.02K | 296,333 |
| Andrew J. Fromkin Director | May 28, 2026 | Sale | −11,483 | $32.64 | $374.81K | 284,850 |
| Andrew J. Fromkin Director | May 28, 2026 | Sale | −210,468 | $33.56 | $7.06M | 74,382 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +77,181 | $8.43 | $650.64K | 280,073 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −1,168 | $32.15 | $37.55K | 243,805 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −1,698 | $32.95 | $55.95K | 242,107 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −249 | $30.41 | $7.57K | 244,973 |
| Atul Pande Director | May 20, 2026 | Sale(10b5-1 plan) | −6,000 | $32.00 | $192.00K | 116,731 |
| Atul Pande Director | May 20, 2026 | Option exercise | +6,000 | $8.43 | $50.58K | 122,731 |
| Robert Graham Susman Director | May 1, 2026 | Sale(10b5-1 plan) | −2,502 | $27.17 | $67.98K | 36,394 |
| Jay S. Stout Chief Technology Officer | Apr 23, 2026 | Sale | −2,754 | $29.62 | $81.57K | 251,685 |
| Tiago Girao Chief Financial Officer | Apr 23, 2026 | Sale | −25,760 | $29.62 | $763.01K | 247,596 |
| Tuyl Christopher Van Chief Legal Officer | Apr 8, 2026 | Sale | −5,165 | $24.83 | $128.25K | 183,231 |
| Jay S. Stout Chief Technology Officer | Apr 8, 2026 | Sale | −1,518 | $24.83 | $37.69K | 254,439 |
| Jay S. Stout Chief Technology Officer | Apr 8, 2026 | Sale | −8,614 | $24.83 | $213.89K | 255,957 |
| Melanie Gloria Chief Operating Officer | Apr 8, 2026 | Sale | −8,722 | $24.83 | $216.57K | 245,222 |
| Melanie Gloria Chief Operating Officer | Apr 7, 2026 | Award | +83,671 | – | – | 253,944 |
| Andrew J. Fromkin Director | Apr 7, 2026 | Award | +13,880 | – | – | 99,732 |
| Douglas J. Hughes Director | Apr 7, 2026 | Award | +13,880 | – | – | 134,653 |
| Jake Bauer Director | Apr 7, 2026 | Award | +13,880 | – | – | 38,896 |
| Atul Pande Director | Apr 7, 2026 | Award | +13,880 | – | – | 116,731 |
| Eric Venker Chief Executive Officer, Director | Apr 7, 2026 | Award | +232,252 | – | – | 251,813 |
| Tiago Girao Chief Financial Officer | Apr 7, 2026 | Award | +64,968 | – | – | 273,356 |
| Jay S. Stout Chief Technology Officer | Apr 7, 2026 | Award | +66,937 | – | – | 264,571 |
| Robert Graham Susman Director | Apr 7, 2026 | Award | +13,880 | – | – | 38,896 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| S. Stout Jay Officer | Jun 26, 2026 | 40,000 | $1.53M | Jun 26, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Adair Van Tuyl Chris Officer, Director | Jun 26, 2026 | 17,824 | $682.80K | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Gloria Melanie Officer | Jun 26, 2026 | 17,714 | $678.55K | Jun 26, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Girao Tiago Officer | Jun 26, 2026 | 10,000 | $384.64K | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Pande Atul Director | Jun 15, 2026 | 6,000 | $201.72K | Jun 15, 2026 | Exercise of Stock Options |
| J. Fromkin Andrew Director | May 28, 2026 | 221,951 | $7.44M | May 28, 2026 | Exercise of options under a registered plan |
| Pande Atul Director | May 20, 2026 | 6,000 | $157.74K | May 20, 2026 | Exercise of Stock Options |
| G. Susman Robert Director | May 1, 2026 | 2,502 | $67.92K | May 1, 2026 | Restricted Stock Units |
| Geffner Michael Officer | Feb 10, 2026 | 5,800 | $155.24K | Feb 10, 2026 | Restricted Stock |
| J. Fromkin Andrew Director | Dec 1, 2025 | 22,249 | $537.31K | Dec 1, 2025 | Restricted Stock Units |
| Hughes Douglas Director | Dec 1, 2025 | 15,000 | $362.25K | Dec 1, 2025 | Restricted Stock Units |
| Geffner Michael Officer | Nov 26, 2025 | 50,000 | $1.19M | Nov 26, 2025 | Stock Option Exercise |
| Geffner Michael Officer | Nov 25, 2025 | 103,897 | $2.43M | Nov 25, 2025 | Stock Option Exercise |
| Macias William Officer | Jun 25, 2025 | 30,000 | $474.86K | Jun 25, 2025 | Restricted Stock |
| Macias William Officer | Jun 13, 2025 | 50,000 | $778.49K | Jun 13, 2025 | Restricted Stock |